Veterinary Biomarkers Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type (Companion Animals, Production Animals), By Product Type (Biomarkers, Kits & Reagents, Biomarker Readers), By Application (Disease Diagnostics, Preclinical Research, Others), By Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor, Others), By Region, & Competition, 2020-2030F

Market Overview

Global Veterinary Biomarkers Market was valued at USD 965.53 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 12.30% through 2030. The Global Veterinary Biomarkers Market refers to the sector within the veterinary healthcare industry that deals with the use of biomarkers for diagnosing diseases, monitoring animal health, and assessing treatment efficacy in animals. Biomarkers are measurable indicators, such as proteins, genes, or metabolites, that can be used to detect and quantify various physiological and pathological processes in animals.

Key Market Drivers

Rising Prevalence of Animal Diseases and Zoonotic Infections

The rising prevalence of animal diseases and zoonotic infections is a critical factor driving the growth of the Global Medical Scheduling Software Market. Globally, zoonotic diseases account for approximately one billion illness cases and millions of fatalities annually. Zoonoses comprise 60% of all newly emerging infectious diseases, underscoring their significant public health impact. Over the past 30 years, more than 30 novel human pathogens have been identified, with 75% originating from animals, highlighting the critical need for enhanced disease surveillance, veterinary healthcare advancements, and cross-sectoral collaboration to mitigate the risks of animal-to-human transmission. As veterinary clinics, hospitals, research centers, and government agencies strive to manage the increasing burden of infectious and chronic diseases in animals, the demand for efficient appointment scheduling, resource allocation, and workflow optimization is escalating. Below is an in-depth analysis of how the growing incidence of animal-related diseases is fueling the expansion of medical scheduling software in the veterinary and broader healthcare sectors.

The increasing prevalence of infectious and chronic diseases in animals—such as rabies, avian influenza, foot-and-mouth disease, and leptospirosis—has led to a surge in veterinary consultations. Approximately 23% of dogs and 39% of cats are not receiving regular booster vaccinations, highlighting a significant gap in routine pet immunization compliance. Veterinary clinics and hospitals are experiencing: Higher patient volumes, leading to appointment scheduling complexities, Urgent cases requiring immediate consultation, necessitating flexible scheduling solutions, Regular check-ups for disease monitoring, increasing the need for automated appointment reminders. Medical scheduling software helps veterinary professionals efficiently manage patient flow, reduce wait times, and optimize emergency case prioritization, ensuring better disease control and treatment outcomes. Zoonotic diseases—those transmissible between animals and humans—are a global health concern. Notable outbreaks, such as COVID-19 (suspected zoonotic origin) and Ebola, have heightened awareness of the need for efficient healthcare coordination. Government agencies, research institutions, and veterinary clinics must work together to track and manage disease outbreaks. Medical scheduling software enables streamlined cross-sector collaboration by integrating data-sharing capabilities for veterinarians, epidemiologists, and human healthcare providers. The One Health approach, which emphasizes human-animal-environment health interconnectivity, further increases the demand for scheduling tools that facilitate multidisciplinary disease response strategies. By improving inter-agency scheduling and communication, medical scheduling software enhances rapid response efforts, helping prevent disease spread.

Growing Companion Animal Population and Humanization of Pets

The Global Veterinary Biomarkers Market is experiencing robust growth, driven in part by the increasing companion animal population and the growing trend of pet humanization. The pet humanization trend is gaining momentum across the Asia-Pacific region, particularly in China, where pet ownership attitudes are evolving rapidly. A recent survey indicates that 55% of Chinese pet owners perceive their cats and dogs as their children, while 28% regard them as family members, and 7.5% consider them companions or friends. This shift in mindset is driving increased spending on premium pet care products, nutrition, and lifestyle services, aligning closely with human wellness trends. As more individuals consider pets as family members, they are willing to invest in preventive healthcare, advanced diagnostics, and personalized treatments. Biomarker-based veterinary diagnostics play a crucial role in enhancing pet healthcare by enabling early disease detection, real-time health monitoring, and customized treatment plans. Below is a detailed analysis of how these factors are driving market expansion. The global companion animal population—particularly dogs and cats—has been rising steadily due to increasing urbanization, changing lifestyles, and the psychological benefits of pet ownership. The 2024 Global Pet Parent Study estimates the worldwide pet population at approximately 1 billion. The study reveals a higher cat ownership rate among men (52%) compared to women (48%). Additionally, among the 56% of respondents who own a cat or dog, 47% are first-time pet owners, reflecting a notable rise in new pet adoption. Countries such as the United States, Canada, China, India, and several European nations have seen a significant increase in pet adoption. The 2024 APPA National Pet Owners Survey, cited in APPA's State of the Industry Report, estimates that 82 million U.S. households own a pet. Among them, 58 million own dogs, 40 million own cats, 9 million have freshwater fish, 6 million keep reptiles, 5 million own birds, 5 million have small animals, 2 million own horses, and 1 million have saltwater fish. The shift in consumer mindset from pet ownership to pet parenting has led to increased spending on high-quality veterinary services, including diagnostics and preventive treatments.

With pet owners becoming more proactive about their pets’ health, there is a growing preference for early disease detection and preventive veterinary care, which is significantly driving the adoption of biomarkers. Traditional veterinary diagnostics often focus on treating diseases after symptoms appear, leading to delayed interventions. Biomarkers, on the other hand, enable early detection of diseases, such as cancer, kidney disease, heart conditions, and metabolic disorders, improving treatment outcomes. Cardiac Biomarkers (NT-proBNP, cTnI): Used for detecting early-stage heart disease in dogs and cats. Inflammatory Biomarkers (CRP, SAA): Help diagnose infections and inflammatory conditions before visible symptoms emerge. Oncology Biomarkers (Thymidine Kinase, CEA, PSA-like markers): Detect cancer at earlier stages, improving survival rates in companion animals. The demand for these tests has increased significantly as pet parents seek more comprehensive and non-invasive diagnostic options, making biomarkers an essential part of modern veterinary medicine.

Download Free Sample Report

Key Market Challenges

Validation and Standardization

Validating and standardizing biomarker assays for veterinary use is essential for ensuring accuracy and reliability. Establishing consistent standards and methodologies is challenging due to the diversity of animal species, breeds, and health conditions. This lack of standardization can hinder the widespread adoption of biomarker-based diagnostics and treatments.

Cost Constraints

Cost is a significant barrier to the adoption of biomarker-based diagnostics and treatments, particularly in resource-limited settings. Developing biomarker assays and acquiring the necessary equipment can be expensive. Reducing costs while maintaining quality is an ongoing challenge for market players.

Education and Awareness

Many veterinarians and pet owners may not be fully aware of the benefits of biomarker-based diagnostics and personalized veterinary care. Education and awareness campaigns are essential to inform stakeholders about the advantages of biomarkers in early disease detection, treatment optimization, and preventive care.

Data Privacy and Security

Biomarker-based diagnostics generate a wealth of sensitive data, including genetic information. Ensuring the privacy and security of this data is crucial to gaining the trust of pet owners and maintaining ethical standards. Compliance with data protection regulations poses an additional challenge for market players.

Key Market Trends

Rise of Point-of-Care Diagnostics

Point-of-care diagnostics are revolutionizing veterinary medicine by providing rapid and on-site testing capabilities. These portable and user-friendly devices allow veterinarians to perform biomarker-based tests right in the clinic, enabling quicker diagnoses and immediate treatment decisions. The convenience of point-of-care testing is expected to drive its adoption in veterinary practices.

Advancements in Genomic Biomarkers

Genomic biomarkers, which involve the study of an animal's genetic material, are gaining prominence in veterinary medicine. These biomarkers provide insights into an animal's predisposition to diseases, helping veterinarians tailor preventive measures and early screening based on genetic risk factors.

Microbiome and Metabolomics Biomarkers

Research into the microbiome and metabolomics is expanding our understanding of how gut health and metabolism influence overall animal well-being. Biomarkers associated with the microbiome and metabolomics are expected to play a more significant role in disease diagnosis and dietary recommendations for animals.

Immunotherapy and Targeted Treatments

Immunotherapy and targeted treatments are emerging as powerful tools in veterinary medicine. Biomarkers play a crucial role in identifying suitable candidates for these therapies and monitoring treatment responses. Expect to see more biomarker-driven personalized treatment plans for animals with cancer and immune-related disorders.

Segmental Insights

Animal Type Insights

Based on the category of Animal Type, the companion animals segment holds the largest market share, driven by increasing pet ownership, higher spending on veterinary care, and advancements in diagnostic technologies. Companion animals—primarily dogs and cats, along with smaller pets such as rabbits and birds—are benefiting from a surge in preventive healthcare and personalized treatment approaches, making biomarkers an essential tool in modern veterinary diagnostics. In the United States, the number of households with at least one dog reached 69 million in 2020, accounting for 54% of all homes, up from 50% in 2018, reflecting a notable rise in pet ownership. The growing global companion animal population is a primary driver of the veterinary biomarkers market. Pet humanization trends have led to increased veterinary visits, with pet owners treating their animals as family members and prioritizing their healthcare. Urbanization, changing lifestyles, and the emotional benefits of pet companionship have further fueled pet adoption, particularly in North America, Europe, and parts of Asia-Pacific. As pet ownership rises, the demand for advanced veterinary diagnostics, including biomarker-based testing, continues to grow.

With the humanization of pets, pet owners are more willing to spend on preventive care, wellness programs, and early disease detection. Pet insurance adoption is rising, particularly in North America and Europe, covering biomarker-based diagnostic tests for conditions such as cancer, kidney disease, and heart disease. Companion animals receive more frequent veterinary check-ups compared to livestock, leading to higher utilization of biomarker-based screening tests. This shift from reactive to preventive veterinary care is significantly boosting the adoption of biomarker-based diagnostics.

Product Type Insights

In 2024, Based on the category of Product Type, the the biomarkers segment holds the largest share, driven by increasing demand for early disease detection, precision medicine, and non-invasive diagnostics. Veterinary biomarkers—biological indicators used to diagnose diseases, monitor treatment efficacy, and assess overall health—are revolutionizing animal healthcare by offering faster, more accurate, and cost-effective diagnostic solutions compared to traditional methods.

Traditional veterinary diagnostics often rely on clinical symptoms that appear in later disease stages, leading to delayed treatment. Biomarkers enable pre-symptomatic disease detection, allowing veterinarians to initiate early interventions and improve health outcomes. Preventive healthcare is gaining traction, with pet owners and livestock producers investing in routine biomarker screenings to detect conditions such as cancer, organ dysfunction, metabolic disorders, and infections. This shift toward proactive veterinary medicine is fueling the demand for biomarker-based diagnostic tools. Innovations in biotechnology, molecular diagnostics, and bioinformatics have expanded the role of biomarkers in veterinary medicine. Portable and real-time biomarker testing kits allow veterinarians to diagnose diseases on-site, reducing diagnostic turnaround times. Advanced genetic biomarker analysis enables personalized veterinary treatments, identifying hereditary disease risks in companion animals and livestock. Artificial intelligence (AI) enhances biomarker analysis by detecting disease patterns, predicting health risks, and optimizing treatment plans. Biomarkers derived from blood, saliva, urine, and fecal samples offer pain-free diagnostic options, improving pet owner compliance and veterinary efficiency. As diagnostic capabilities evolve, biomarker-based testing is becoming the preferred choice in veterinary medicine, strengthening its market dominance.

Download Free Sample Report

Regional Insights

In 2024, The North America region holds the largest share in the global veterinary biomarkers market, driven by high pet ownership rates, advanced veterinary infrastructure, strong regulatory frameworks, and rising investments in animal healthcare. The United States and Canada, in particular, have well-established veterinary diagnostic networks, cutting-edge research facilities, and increasing demand for precision veterinary medicine, making North America the dominant region in this sector. North America is home to some of the most advanced veterinary hospitals, research centers, and diagnostic laboratories, ensuring widespread accessibility and adoption of biomarker-based diagnostics.

The U.S. and Canada have a high density of veterinary clinics, referral hospitals, and specialty animal health centers, increasing demand for biomarker-driven diagnostics. Leading companies such as IDEXX Laboratories, Zoetis, and Antech Diagnostics dominate the North American market, offering specialized biomarker-based testing services. Veterinary clinics and mobile veterinary services are increasingly adopting rapid biomarker-based diagnostic kits, enabling on-the-spot disease detection and monitoring. With a highly developed veterinary infrastructure, North America continues to lead in biomarker adoption and innovation

Recent Developments

• In January 2025, Virbac, a global leader in animal health, has joined forces with Emmyon, Inc., a biotechnology company specializing in skeletal muscle biology, to introduce URSOLYX™ Soft Chews—a pioneering muscle support supplement for animals. This first-in-class formulation leverages ursolic acid, a compound scientifically proven to modulate mRNA expression in skeletal muscle, promoting muscle health and strength.
• In September 2024, Boehringer Ingelheim has acquired Saiba Animal Health, integrating its innovative technology platform into the company’s expanding pet therapeutics R&D pipeline. This strategic acquisition enhances Boehringer Ingelheim’s capabilities in the rapidly growing companion animal therapeutics sector, reinforcing its commitment to advancing novel treatment solutions.
• In August 2024, FidoCure has been granted a groundbreaking patent by the U.S. Patent and Trademark Office for an innovative targeted therapy and biomarker designed for the treatment of canine cancer. This industry-first breakthrough was made possible through an AI-powered approach, which utilizes real-world veterinary clinical data to enhance treatment precision, accessibility, and efficiency.
• In July 2024, Invetx Inc., a leader in protein-based therapeutics for animal health, has entered into an acquisition agreement with Dechra Pharmaceuticals Limited, a global veterinary pharmaceuticals specialist, in a transaction valued at up to $520 million on a cash-free, debt-free basis.
• In October 2021, Zoetis inaugurated a fresh production facility in Ireland, thereby increasing its production capabilities for monoclonal antibodies.  

Key Market Players

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• Acuvet Biotech
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

Report Scope:

In this report, the Global Veterinary Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Biomarkers Market, By Animal Type:

o   Companion Animals

o   Production Animals

• Veterinary Biomarkers Market, By Product Type:

o   Biomarkers

o   Kits & Reagents

o   Biomarker Readers

• Veterinary Biomarkers Market, By Application:

o   Disease Diagnostics

o   Preclinical Research

o   Others

• Veterinary Biomarkers Market, By Disease Type:

o   Inflammatory & Infectious Diseases

o   Cardiovascular Diseases

o   Skeletal Muscle Diseases

o   Tumor

o   Others

• Veterinary Biomarkers Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Biomarkers Market.

Available Customizations:

Global Veterinary Biomarkers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).